About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Sheesh | Main | Your Paper (That Sack of Raving Nonsense) Has Been Accepted! »

April 16, 2009

Deuterated Drugs: A Side Effect Already?

Email This Entry

Posted by Derek

Well, this isn't a toxicological side effect so much as an analytical chemistry one. Nature reports that forensic scientists are quite worried about the idea of deuterated drugs catching on, because they use deuterated versions of common pharmaceuticals as analytical reference standards. A lot of common analysis methods for the drugs in question would have to be junked for anyone taking the deuterated compound. And with both versions on the market, toxicologists would always be uncertain about where they stood, particularly by legal evidence standards.

Comments (3) + TrackBacks (0) | Category:


1. carras on April 16, 2009 10:50 AM writes...

That is exactly my case: in my lab we use many deuterated standards for our analysis (it is an absolute must when analysing drug residues in biological fluids or tissues using LC/MS). I don't know much about how these things are synthezised but I've always figured they could be made with 15N, 13C and so on. For example I am using 37Cl-cloranphenicol as internal standard.

Permalink to Comment

2. Celeste on April 16, 2009 8:42 PM writes...

As an analytical chemist, I can attest that widespread use of deuterated drugs would undermine many LC/MS methods. Thanks for posting, as the concept of deuterated drugs is news to me. I will certainly be on the lookout now.

Permalink to Comment

3. tom on April 18, 2009 2:49 PM writes...

Yes, deuterated standards make life much easier, but if you are really good you can also work without it in many cases. You only have to demonstrate that your LC-MS methods are robust enough with respect to various food components, co-medication and other matrix effects.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry